The renin-angiotensin system meets the hallmarks of cancer

被引：114

作者：

Wegman-Ostrosky, Talia ^{[1
,2
]}

Soto-Reyes, Ernesto ^{[1
]}

Vidal-Millan, Silvia ^{[1
]}

Sanchez-Corona, Jose ^{[2
,3
]}

机构：

[1] Inst Nacl Cancerol, Div Invest, Mexico City, DF, Mexico

[2] Univ Guadalajara, Inst Genet Humana, Guadalajara 44430, Jalisco, Mexico

[3] Inst Mexicano Seguro Social, Ctr Invest Biomed Occidente, Mexico City, DF, Mexico

来源：

JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM | 2015年 / 16卷 / 02期

关键词：

Renin-angiotensin system; angiotensinogen; angiotensin; cancer; hallmarks; II TYPE-1 RECEPTOR; PROSTATE-CANCER; TUMOR-GROWTH; ANGIOGENESIS; EXPRESSION; BLOCKADE; INHIBITORS; RISK; PROLIFERATION; SUPPRESSION;

D O I：

10.1177/1470320313496858

中图分类号：

R6 [外科学];

学科分类号：

1002 ; 100210 ;

摘要：

The hallmarks of cancer are described as the distinctive and complementary capacities that cells must acquire during the multistep development of becoming a cancer cell that allow them to survive, proliferate and disseminate. The renin-angiotensin system (RAS) was first discovered and extensively studied in the physiological regulation of systemic arterial pressure. RAS signalling increases cell proliferation in malignancy by directly affecting tumour and stromal cells and by indirectly modulating the growth of vascular cells during angiogenesis. We aim to describe and give a general view of how the RAS is involved in several hallmarks of cancer and how this could open a window to several interesting treatments.

引用

页码：227 / 233

页数：7

共 48 条

[21] Angiotensin-(1-7) attenuates metastatic prostate cancer and reduces osteoclastogenesis [J].

Krishnan, Bhavani ;

Smith, Thomas L. ;

Dubey, Purnima ;

Zapadka, Michael E. ;

Torti, Frank M. ;

Willingham, Mark C. ;

Tallant, E. Ann ;

Gallagher, Patricia E. .

PROSTATE, 2013, 73 (01) :71-82

[22] Angiotensin-(1-7) reduces proliferation and angiogenesis of human prostate cancer xenografts with a decrease in angiogenic factors and an increase in sFlt-1 [J].

Krishnan, Bhavani ;

Torti, Frank M. ;

Gallagher, Patricia E. ;

Tallant, E. Ann .

PROSTATE, 2013, 73 (01) :60-70

[23] Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? [J].

Lever, AF ;

Hole, DJ ;

Gillis, CR ;

McCallum, IR ;

McInnes, GT ;

MacKinnon, PL ;

Meredith, PA ;

Murray, LS ;

Reid, JL ;

Robertson, JWK .

LANCET, 1998, 352 (9123) :179-184

[24]

Lewandowska U, 2011, ENDOKRYNOL POL, V62, P151

[25] Angiotensin type 2 receptor-mediated apoptosis of human prostate cancer cells [J].

Li, Hongwei ;

Qi, Yanfei ;

Li, Chengyao ;

Braseth, Leah N. ;

Gao, Yongxin ;

Shabashvili, Arseniy E. ;

Katovich, Michael J. ;

Sumners, Colin .

MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12) :3255-3265

[26] Angiotensin II-induced neural differentiation via angiotensin II type 2 (AT2) receptor-MMS2 cascade involving interaction between AT2 receptor-interacting protein and Src homology 2 domain-containing protein-tyrosine phosphatase 1 [J].

Li, Jian-Mei ;

Mogi, Masaki ;

Tsukuda, Kana ;

Tomochika, Hirokazu ;

Iwanami, Jun ;

Min, Li-Juan ;

Nahmias, Clara ;

Iwai, Masaru ;

Horiuchi, Masatsugu .

MOLECULAR ENDOCRINOLOGY, 2007, 21 (02) :499-511

[27] Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: current status [J].

Ma, Terry K. W. ;

Kam, Kevin K. H. ;

Yan, Bryan P. ;

Lam, Yat-Yin .

BRITISH JOURNAL OF PHARMACOLOGY, 2010, 160 (06) :1273-1292

[28]

Miyajima A, 2002, CANCER RES, V62, P4176

[29] Drug repositioning: Re-investigating existing drugs for new therapeutic indications [J].

Padhy, B. M. ;

Gupta, Y. K. .

JOURNAL OF POSTGRADUATE MEDICINE, 2011, 57 (02) :153-160

[30] The renin-angiotensin system: a target of and contributor to dyslipidemias, altered glucose homeostasis, and hypertension of the metabolic syndrome [J].

Putnam, Kelly ;

Shoemaker, Robin ;

Yiannikouris, Frederique ;

Cassis, Lisa A. .

AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2012, 302 (06) :H1219-H1230

← 1 2 3 4 5 →